TaiMed Biologics (4147) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TaiMed Biologics (4147) has a cash flow conversion efficiency ratio of 0.007x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$25.95 Million ≈ $817.63K USD) by net assets (NT$3.86 Billion ≈ $121.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TaiMed Biologics liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
TaiMed Biologics - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how TaiMed Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
TaiMed Biologics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TaiMed Biologics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
goeasy Ltd
TO:GSY
|
0.228x |
|
Capital Futures Corp
TW:6024
|
0.114x |
|
Bannari Amman Sugars Limited
NSE:BANARISUG
|
0.130x |
|
Solaer Israel Ltd
TA:SOLR
|
-0.039x |
|
KENGIC Intelligent Technology Co. Ltd. A
SHG:688455
|
N/A |
|
Jiayuan Science and Technology Co.Ltd.
SHE:301117
|
N/A |
|
Shanghai Shentong Metro Co Ltd
SHG:600834
|
-0.012x |
|
Beijing Haohan Data Technology Co. Ltd. A
SHG:688292
|
N/A |
Annual Cash Flow Conversion Efficiency for TaiMed Biologics (2015–2025)
The table below shows the annual cash flow conversion efficiency of TaiMed Biologics from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see 4147 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$3.86 Billion ≈ $121.54 Million |
NT$191.14 Million ≈ $6.02 Million |
0.050x | +152.52% |
| 2024-12-31 | NT$4.02 Billion ≈ $126.74 Million |
NT$-379.55 Million ≈ $-11.96 Million |
-0.094x | -845.68% |
| 2023-12-31 | NT$2.57 Billion ≈ $80.85 Million |
NT$-25.60 Million ≈ $-806.57K |
-0.010x | +95.52% |
| 2022-12-31 | NT$2.71 Billion ≈ $85.53 Million |
NT$-605.21 Million ≈ $-19.07 Million |
-0.223x | -210.36% |
| 2021-12-31 | NT$2.94 Billion ≈ $92.67 Million |
NT$-211.28 Million ≈ $-6.66 Million |
-0.072x | -21.50% |
| 2020-12-31 | NT$3.42 Billion ≈ $107.62 Million |
NT$-201.94 Million ≈ $-6.36 Million |
-0.059x | +67.65% |
| 2019-12-31 | NT$3.59 Billion ≈ $112.99 Million |
NT$-655.31 Million ≈ $-20.65 Million |
-0.183x | -42.60% |
| 2018-12-31 | NT$4.08 Billion ≈ $128.56 Million |
NT$-522.86 Million ≈ $-16.47 Million |
-0.128x | -6.49% |
| 2017-12-31 | NT$4.29 Billion ≈ $135.23 Million |
NT$-516.48 Million ≈ $-16.27 Million |
-0.120x | -229.21% |
| 2016-12-31 | NT$4.71 Billion ≈ $148.51 Million |
NT$-172.29 Million ≈ $-5.43 Million |
-0.037x | +59.87% |
| 2015-12-31 | NT$4.90 Billion ≈ $154.37 Million |
NT$-446.26 Million ≈ $-14.06 Million |
-0.091x | -- |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more